The Danish company Lundbeck announced that it was stopping the delivery of the drugs Nortrilen and Redomex to Belgium. “A decision to the detriment of the well-being of patients,” notes Test-Achats.
The pharmaceutical company Lundbeck announced that she put an end to the delivery of two drugs to Belgium. It is Nortrilen (nortriptyline) and Redomex (amitriptyline), two medications used to combat depression.
Both Nortrilen and Redomex have reached the end of their license. In other words, generic drug manufacturers are now allowed to produce them. The Danish company justified the withdrawal of the two drugs, scheduled for June, for economic reasons : the cost of maintaining them on the market exceeds the profits generated.
Increase in bill
“Public authorities must be better armed in their standoff with pharmaceutical companies when the latter, as in the present case, do not assume their responsibility towards society and put the well-being of patients at risk. in danger,” believes the consumers’ association. And to remember that Redomex is part of the list of medications deemed essential by the World Health Organization (WHO), i.e. medicines that should be available in all countries.
In order to obtain supplies, patients have the option of having them made by a pharmacist or going abroad to buy them. In both cases, however, patients face increased costs. While the purchase price is 1.65 euros, in the absence of reimbursement, the cost should be between 8 and 13 euros.
